产品
编 号：F744036
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1314241-10-5
产品详情
生物活性：
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement.
体内研究：
Orticumab (10 毫克/小鼠；腹腔注射；每周一次，持续 3 周) 减少主动脉弓中的动脉粥样硬化，减少 CD68 巨噬细胞瓣膜下斑块染色。Animal Model:B6.lpr.ApoE-/- mice (18-week-old) fed with high-fat diet (HFD)
Dosage:10 mg/mouse
Administration:Intraperitoneal injection; once weekly for 3 weeks
Result:Reduced atherosclerosis in the aortic arch by 42.8%, decreased the CD68-macrophage subvalvular plaque staining by 30.5%.
体外研究：
Orticumab (10 μg/mL；24 小时) 增加 oxLDL 刺激后体外培养的 PBMC 中的 CD14+ ICOS-L+ 群体。
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement.
体内研究：
Orticumab (10 毫克/小鼠；腹腔注射；每周一次，持续 3 周) 减少主动脉弓中的动脉粥样硬化，减少 CD68 巨噬细胞瓣膜下斑块染色。Animal Model:B6.lpr.ApoE-/- mice (18-week-old) fed with high-fat diet (HFD)
Dosage:10 mg/mouse
Administration:Intraperitoneal injection; once weekly for 3 weeks
Result:Reduced atherosclerosis in the aortic arch by 42.8%, decreased the CD68-macrophage subvalvular plaque staining by 30.5%.
体外研究：
Orticumab (10 μg/mL；24 小时) 增加 oxLDL 刺激后体外培养的 PBMC 中的 CD14+ ICOS-L+ 群体。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备